It is reported that T‑2 toxin remodels APP and Tau homeostasis, featuring an early decrease in full‑length APP and a delayed, sustained increase in Tau phosphorylation and total Tau, accompanied by dynamic cytokine release.
Abstract
Environmental mycotoxins are pervasive exposures, yet how they perturb Alzheimer's disease (AD)-relevant proteostasis remains unclear. We treated SH-SY5Y cells with low-dose T-2 toxin (6nM) for 24h, and profiled AD-relevant protein changes alongside transcriptomic, circadian, and senescence-related readouts. We report that T‑2 toxin remodels APP and Tau homeostasis, featuring an early decrease in full‑length APP and a delayed, sustained increase in Tau phosphorylation and total Tau, accompanied by dynamic cytokine release. RNA‑seq at 12h revealed a p53‑centered stress response and enrichment of circadian‑related pathways. Cosinor analysis indicated that CLOCK rhythmicity is preserved but reparameterized following T-2 toxin exposure, with a marked phase shift and an elevated mesor. Pharmacological disruption of CLOCK attenuated p53 induction and Tau elevation, whereas inhibition of p53 partially restored APP and reduced Tau changes while reshaping CLOCK abundance and localization, consistent with CLOCK-p53 cross‑regulation. T‑2 toxin also induced a time‑dependent senescence‑like phenotype that was attenuated by CLOCK and/or p53 inhibition. Post‑treatment with senolytic drugs dasatinib and quercetin reduced SA‑β‑gal burden, dampened p53 signaling, and improved the APP/Tau profile. Together, these data link T‑2 toxin exposure to AD‑relevant proteostasis remodeling through a CLOCK-p53-senescence axis and suggest circadian and senescence‑targeting strategies as complementary intervention points.
This review synthesizes current knowledge regarding piRNA dysregulation in AD, examining mechanistic links between piRNA loss, transposable element activation, Aβ toxicity, and tau pathology while evaluating therapeutic implications.
S. Taherkhani, Zeynab Sharifiaghdam, Parnian Amani· SVOA Neurology· 0 citations
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, amyloid-β and tau aggregation, and chronic neuroinflammation, processes that are tightly coupled to circadian and metabolic dysfunction. REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) are ligand-dependent nuclear receptors that function as transcription...
Fahmida Shabnam, Meenakshi Singh, Rajesh H. Amin et al.· British Journal of Biomedica...· 0 citations
The development of Alzheimer disease (AD) involves a cluster of pathogenic processes, including amyloid-beta (Aβ) deposition, tau-mediated neurodegeneration, chronic neuroinflammation, oxidative stress (OS), metabolic dysregulation, and disruption of circadian rhythms. Nuclear hormone receptor, Retinoic Acid-Related Or...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) accumulation and oxidative stress, with aging being its greatest risk factor. Age-related glutathione (GSH) depletion may increase neuronal vulnerability to Aβ toxicity, but the underlying mechanisms remain unclear. Her...
Kazi Rafsan Radeen, Cai-Li Hao, Zong-Bo Wei et al.· Free Radical Biology & Medic...· 0 citations
Findings identify WWOX as a regulator of neuronal metabolic state, linking genetic risk to amyloid pathology via metabolic reprogramming, and highlight WWOX activation as a potential therapeutic strategy in Alzheimer’s disease.
Hannah J. Lucas-Clarke, D. Maddison, L. Amadio et al.· Brain Communications· 0 citations
Investigating the mechanisms underlying the reduction of p-tau217+ EVs to uncover AD therapeutic targets reveals a role of HSPA8 in regulating the MVB-mediated EV release and tau propagation, and highlights HSPA8 as a promising therapeutic target for modifying AD progression.
Bin Xu, Zhen Guo, Jun Chen et al.· Translational Neurodegenerat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.